BiotechTube

Trastuzumab deruxtecan + Rilvegostomig + Pembrolizumab + Carboplatin + Paclitaxel + Docetaxel

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Endometrial Cancer

Conditions

Endometrial Cancer

Trial Timeline

Mar 27, 2025 → Feb 19, 2031

NCT ID
NCT06989112

About Trastuzumab deruxtecan + Rilvegostomig + Pembrolizumab + Carboplatin + Paclitaxel + Docetaxel

Trastuzumab deruxtecan + Rilvegostomig + Pembrolizumab + Carboplatin + Paclitaxel + Docetaxel is a phase 3 stage product being developed by Daiichi Sankyo for Endometrial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06989112. Target conditions include Endometrial Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06989112Phase 3Recruiting

Competing Products

20 competing products in Endometrial Cancer

See all competitors
ProductCompanyStageHype Score
Atezolizumab - 28 Day Cycle + Bevacizumab + Ipatasertib + Talazoparib + Trastuzumab emtansine + Tiragolumab + Atezolizumab - 21 Day Cycle + Inavolisib + Letrozole + Giredestrant + AbemaciclibEli LillyPhase 1/2
41
ACR-368 + GemcitabineAcrivon TherapeuticsPhase 2
44
Sodium Cridanimod + progestin therapyXenetic BiosciencesPhase 2
44
Letrozole + Abemaciclib + LY3023414 + Metformin + Zotatifin + GedatolisibeFFECTOR TherapeuticsPhase 2
44
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab Deruxtecan + ChemotherapyDaiichi SankyoPhase 3
77
Datopotamab deruxtecan (Dato-DXd) + Capecitabine + 5-Fluorouracil + Volrustomig + Carboplatin + Bevacizumab + Rilvegostomig + Prednisone/ prednisolone + CisplatinDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Enfortumab VedotinAstellas PharmaPhase 2
52
Lenvatinib + Pembrolizumab + Paclitaxel + CarboplatinEisaiPhase 3
77
LenvatinibEisaiPhase 2
52
Pembrolizumab + Lenvatinib + Paclitaxel + DoxorubicinEisaiPhase 3
77
Lenvatinib + Pembrolizumab + Paclitaxel + CarboplatinEisaiPhase 3
77
E7386 + Lenvatinib + Doxorubicin + PaclitaxelEisaiPhase 1/2
41
Abemaciclib + LetrozoleEli LillyPhase 2
52
Abemaciclib + Anastrozole + LetrozoleEli LillyPhase 2
52
LY3023414Eli LillyPhase 2
52
arzoxifene hydrochlorideEli LillyPhase 2
52
Abemaciclib + Letrozole + PembrolizumabEli LillyPhase 2
52
Trabectedin + DexamethasoneJohnson & JohnsonPhase 2
52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85